NCT00790036
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Nowotwór
DLBCL
Chorzy
III/IV stopień, CR po chemioterapii z rytuksymabem
Faza badania
III
Sponsor badania
Novartis
Termin
-
Linki
Dane kontaktowe
Bydgoszcz; Łódź; Lublin; Warszawa